LGM Pharma, a leading provider of tailored API sourcing, contract analytical testing, and CDMO services for the full drug ...

Key Takeaways. LGM Pharma’s Texas expansion targets commercial suppository manufacturing and broader semi-solid/liquid development, aligning with women’s health demand and U.S ...

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO).

Agno Pharma Acquires Actylis’s CDMO Manufacturing Asset, the Legacy Cascade Chemistry Business based in Eugene, Oregon, Strengthening Agno’s US cGMP API Development and Manufacturing Capabilities Agno ...

BOCA RATON, Fla.--(BUSINESS WIRE)--LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product life cycle, today reported that its unique mix of active pharmaceutical ...

Aurobindo Pharma Limited has announced that the United States Food and Drug Administration (USFDA) has classified Unit-V of its wholly owned subsidiary, Apitoria Pharma Private ...

QINGDAO, CHINA, January 19, 2026 /EINPresswire.com/ — As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened ...

AbbVie’s North Chicago expansion adds two state-of-the-art API plants intended to support next-generation neuroscience and obesity portfolios via advanced manufacturing technologies and artificial ...

DUBLIN, May 10, 2021 /PRNewswire/ -- The "Global Active Pharmaceutical Ingredient Market (2020-2025) by Type, Molecule, Product Type, Formulation Type, Manufacturing Type, Synthesis Type, Drug Type, ...

Pakistan's pharmaceutical industry, valued at Rs. 748 billion, faces challenges with API imports. Localizing API production could enhance economic stability and healthcare affordability.

India hosts more active pharmaceutical ingredient (API) manufacturing sites that are compliant with the U.S. Food and Drug Administration than any country outside the U.S., and it produces more ...